Immunoglobulin G (IgG) therapy is an established long-term treatment in chronic inflammatory demyelinating polyneuropathy (CIDP) that is commonly administered intravenously (IVIg). The subcutaneous immunoglobulin (SCIg) administration route is a safe and effective alternative option, approved by the United States Food and Drug Administration (FDA) in 2018, for maintenance treatment of adults with CIDP. Physicians and patients alike need to be aware of all their treatment options in order to make informed decisions and plan long-term treatment strategies. In this review, we collate the evidence for SCIg in CIDP from all published studies and discuss their implications and translation to clinical practice. We also provide guidance on the practicalities of how and when to transition patients from IVIg to SCIg and ongoing patient support. Evidence suggests that IVIg and SCIg have comparable long-term efficacy in CIDP. However, SCIg can provide additional benefits for some patients, including no requirement for venous access or premedication, and reduced frequency of systemic adverse events. Local-site reactions are more common with SCIg than IVIg, but these are mostly well-tolerated and abate with subsequent infusions. Data suggest that many patients prefer SCIg following transition from IVIg. SCIg preference may be a result of the independence and flexibility associated with self-infusion, whereas IVIg preference may be a result of familiarity and reliance on a healthcare professional for infusions. In practice, individualizing maintenance dosing based on disease behavior and determining the minimally effective IgG dose for individuals are key considerations irrespective of the administration route chosen.

中文翻译：

---

皮下免疫球蛋白治疗慢性炎性脱髓鞘性多发性神经病

免疫球蛋白 G (IgG) 疗法是慢性炎性脱髓鞘性多发性神经病 (CIDP) 的长期治疗方法，通常静脉内给药 (IVIg)。皮下免疫球蛋白 (SCIg) 给药途径是一种安全有效的替代选择，于 2018 年获得美国食品和药物管理局 (FDA) 批准，用于成人 CIDP 维持治疗。医生和患者都需要了解他们的所有治疗选择，以便做出明智的决定并规划长期治疗策略。在这篇综述中，我们从所有已发表的研究中整理了 CIDP 中 SCIg 的证据，并讨论了它们的影响和对临床实践的转化。我们还提供有关如何以及何时将患者从 IVIg 过渡到 SCIg 以及持续的患者支持的实用性指导。有证据表明，IVIg 和 SCIg 在 CIDP 中具有相当的长期疗效。然而，SCIg 可以为一些患者提供额外的好处，包括不需要静脉通路或术前用药，以及减少全身不良事件的频率。SCIg 的局部反应比 IVIg 更常见，但这些反应大多耐受良好，并随着随后的输注而减弱。数据表明，许多患者在从 IVIg 过渡后更喜欢 SCIg。SCIg 偏好可能是与自我输液相关的独立性和灵活性的结果，而 IVIg 偏好可能是熟悉和依赖医疗保健专业人员进行输液的结果。在实践中，